达拉他韦:临床前与临床药代动力学综述
达拉他韦是首创的高选择性HCV NS5A抑制剂,体外活性达皮摩尔级且基因型覆盖广。本综述汇总其吸收、分布、代谢与清除特征,以及肝肾功能不全、食物和药物相互作用对暴露的影响,并给出与CYP3A4抑制剂或诱导剂合用时60mg每日一次的剂量调整建议。
要点
- 达拉他韦经CYP3A4代谢和P-gp排泄,强CYP3A4抑制剂合用时减至30mg每日一次。
- 中度CYP3A4诱导剂合用时增至90mg每日一次,强诱导剂合用禁忌。
- 任何程度肝或肾功能不全均无需调整剂量,年龄、种族、性别不影响暴露。
核心结论
- 达拉他韦药代动力学特征明确,是慢性HCV感染全口服强效且耐受良好方案的组成部分。
研究设计与样本
- 综述汇总达拉他韦的临床前与临床药代动力学研究,包括单次递增和多次递增剂量研究。
主要发现
- 单次递增剂量研究中达拉他韦达峰时间为1-2小时,消除半衰期约10至14小时。
- 多次递增剂量研究中达拉他韦在第4天达到稳态。
- 健康受试者与HCV感染者的达拉他韦暴露相似。
- 年龄、种族或性别等内在因素不影响达拉他韦暴露。
关键数值与推荐
- 与强CYP3A4抑制剂合用时,达拉他韦剂量应从60mg每日一次减至30mg每日一次。
- 与中度CYP3A4诱导剂合用时,达拉他韦剂量应从60mg每日一次增至90mg每日一次。
- 与强CYP3A4诱导剂合用禁忌。
- 与中度CYP3A4抑制剂合用时无需调整达拉他韦剂量。
- 任何程度肝或肾功能不全患者无需调整达拉他韦剂量。
临床怎么用
- 达拉他韦可不受食物或pH调节剂影响给药。
- 仅抑制P-gp而不抑制CYP3A4的合并用药不太可能显著改变达拉他韦暴露。
- 达拉他韦对CYP酶底物药物药代动力学影响的可能性低。
- 除瑞舒伐他汀外,达拉他韦未明显改变转运体底物药物的药代动力学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daclatasvir is a first-in-class, highly selective, hepatitis C virus, non-structural protein 5a polymerase replication complex inhibitor with picomolar potency and broad genotypic coverage in vitro. Daclatasvir undergoes rapid absorption, with a time to reach maximum plasma concentration of 1-2 h and an elimination half-life of ~ 10 to 14 h observed in single-ascending dose studies. Steady state was achieved by day 4 in multiple-ascending dose studies. Daclatasvir can be administered without regard to food or pH modifiers. Daclatasvir exposure is similar between healthy subjects and subjects infected with hepatitis C virus. Intrinsic factors such as age, race, or sex do not impact daclatasvir exposure. No dose adjustment is necessary for patients with any degree of hepatic or renal impairment. Daclatasvir has low-to-moderate clearance with the predominant route of elimination via cytochrome P450 3A4-mediated metabolism and P-glycoprotein excretion and intestinal secretion. Renal clearance is a minor route of elimination for daclatasvir. As a result, the dose of daclatasvir should be reduced from 60 to 30 mg once daily when co-administered with strong inhibitors of cytochrome P450 3A4. No dose adjustment is required when daclatasvir is co-administered with moderate inhibitors of cytochrome P450 3A4. The dose of daclatasvir should be increased from 60 to 90 mg once daily when co-administered with moderate inducers of cytochrome P450 3A4. Co-administration of daclatasvir with strong inducers of cytochrome P450 3A4 is contraindicated. Concurrent medications with inhibitory effects on P-glycoprotein without concurrent inhibition of cytochrome P450 3A4 are unlikely to cause marked changes in daclatasvir exposure, as the clearance of daclatasvir is through both cytochrome P450 3A4 and P-glycoprotein. The potential for daclatasvir to affect the pharmacokinetics of concomitantly administered drugs that are substrates of the cytochrome P450 enzyme system is low. In vitro, daclatasvir is a weak-to-moderate inhibitor of transporters including organic cation transporter 1, P-glycoprotein, organic transporting polypeptide 1B1, organic transporting polypeptide 1B3, and breast cancer resistance protein, although in clinical studies, daclatasvir has not altered the pharmacokinetics of concomitantly administered drugs that are substrates of these transporters to an appreciable degree, except for rosuvastatin. In summary, daclatasvir is a hepatitis C virus, non-structural protein 5a-selective inhibitor with a well-characterized pharmacokinetic profile that forms part of potent and well-tolerated all-oral treatment regimens for chronic hepatitis C virus infection.
引用
- Gandhi Y, Eley T, Fura A, et al. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 2018. PMID: 29353349. doi:10.1007/s40262-017-0624-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。